On February 29th, according to the official website of the Drug Evaluation Center of the National Medical Products Administration, the Class 1 new drug KarXT capsules applied for by Karuna Company have obtained implied permission for clinical trials and are planned to be developed for the treatment of mental and behavioral symptoms related to Alzheimer's disease. Zaiding Pharmaceutical owns the development, production, and commercialization rights of KarXT in Greater China.
According to the medical Rubik's cube data, KarXT (xanomeline tropium) is an oral M1/M4 type muscarine acetylcholine receptor agonist developed by Karuna company. The approved clinical indication for this is Alzheimer's disease-related psychobehavioral symptoms.
Hang Seng Pharmaceutical ETF (159892) holds positions in well-known innovative pharmaceutical industry chain enterprises such as Zhongding Pharmaceutical, WuXi AppTec, WuXi AppTec, and BeiGene, with high R&D investment and strong innovation attributes. With the progress of domestic technology, overseas market business has also been steadily advancing in recent years.